Can clinically validated CASPR2, GABA receptor, and glycine receptor antibodies alter neuronal excitability and synaptic signaling?

Neuronal-surface autoantibodies can be directly pathogenic when they are antigen-specific, clinically concordant, and reach the central nervous system. The strongest evidence concerns disruption of inhibitory signaling or potassium-channel organization, both of which can shift neural networks toward hyperexcitability.

Clinical and functional evidence

• CASPR2 antibodies can disrupt CASPR2-dependent Kv1.1/Kv1.2 potassium-channel organization and conductance. Reduced potassium current provides a direct route to neuronal hyperexcitability; altered AMPA-receptor trafficking and synaptic currents may also contribute to disturbed synaptic function.
• GABA-receptor antibodies, particularly GABA_A receptor antibodies, reduce surface and synaptic receptor availability and can directly inhibit GABAergic currents. The resulting loss of inhibitory transmission supports increased excitability and impaired inhibitory synaptic signaling. Effects attributed to GABA_B receptor antibodies are less fully characterized.
• Glycine-receptor (GlyR) antibodies, especially α1-directed IgG, rapidly and profoundly reduce miniature glycinergic synaptic currents in cultured motor neurons. This is consistent with impaired spinal/brainstem inhibitory signaling and consequent hyperexcitability.

Mechanistic basis

• CASPR2 antibodies interfere with interactions involving contactin-2/TAG-1, disorganizing Kv1-channel complexes and reducing stabilizing outward potassium currents.
• GABA_A receptor antibodies may cross-link and internalize receptors, lowering surface and synaptic receptor density; some additionally exert direct functional inhibition.
• GlyR antibodies can antagonize receptors and promote receptor cross-linking/internalization, reducing surface GlyR expression and glycinergic synaptic currents.

Interpretation

• Clinical attribution depends on validated antigen-specific testing, phenotype concordance, and evidence of CNS access—preferably paired serum and CSF assessment. CASPR2 reactivity should be distinguished from nonspecific VGKC-complex results.
• Bottom line: The claim is supported. Disease-relevant CASPR2, GABA_A, and GlyR antibodies can alter neuronal excitability and synaptic signaling through well-defined receptor- or channel-associated mechanisms, although mechanistic certainty is lower for GABA_B antibodies and GlyR effects in vivo.